Anti-SARS-CoV-2 Receptor-Binding Domain Antibody Evolution after mRNA Vaccination

URL

https://www.nature.com/articles/s41586-021-04060-7

Authors

Alice Cho, Frauke Muecksch, Dennis Schaefer-Babajew, Zijun Wang, Shlomo Finkin, Christian Gaebler, Victor Ramos, Melissa Cipolla, Pilar Mendoza, Marianna Agudelo, Eva Bednarski, Justin DaSilva, Irina Shimeliovich, Juan Dizon, Mridushi Daga, Katrina Millard, Martina Turroja, Fabian Schmidt, Fengwen Zhang, Tarek Ben Tanfous, Mila Jankovic, Thiago Y. Oliveria, Anna Gazumyan, Marina Caskey, Paul D. Bieniasz, Theodora Hatziioannou, and Michel C. Nussenzweig

Published Date

October 7, 2021

Organization

The Rockefeller University

Key Excerpts

“Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell responses that continue to evolve for at least a year. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to mutations found in variants of concern"

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.

Medium

document

Topics

mRNA,natural immunity,vaccines